Budesonide

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.

Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.

• Allergic Reaction
• Allergic Rhinitis (AR)
• Asthma
• Bronchoconstriction
• Chronic Obstructive Pulmonary Disease (COPD)
• Collagenous Colitis
• Crohn's Disease (CD)
• Eosinophilic Esophagitis
• Exacerbation of asthma
• Nasal Congestion
• Nasal Polyps
• Proteinuria
• Pruritus
• Rhino Sinusitis
• Ulcerative Colitis
• Vasomotor Rhinitis
• Corticosteroid-responsive dermatoses
• Mild Crohn’s Disease
• Moderate Crohn’s Disease